文献速递妇科

机器人辅助腹腔镜对比传统腹腔镜与开腹手术治疗子宫内膜癌的生存结局:系统评价与Meta分析

Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2023-05-05

该系统评价与Meta分析检索截至2022年5月24日的多个数据库,比较机器人辅助腹腔镜(RALS)与传统腹腔镜(CLS)和开腹手术(LT)治疗子宫内膜癌的长期生存结局。RALS与CLS在总生存(OS)、无复发生存(RFS)和疾病特异性生存(DSS)上无差异,但RALS相比LT与更优的OS、RFS和DSS显著相关。在早期子宫内膜癌患者中,RALS的OS与CLS相似但RFS更差。

要点

  • RALS与CLS在子宫内膜癌的OS、RFS和DSS上无显著差异。
  • RALS相比LT与更优的OS、RFS和DSS显著相关。
  • 早期子宫内膜癌患者中RALS的OS与CLS相似但RFS更差。

核心结论

  • RALS在子宫内膜癌治疗中是安全的,其长期肿瘤学结局与CLS相当且优于LT。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane、EMBASE和Web of Science直至2022年5月24日,并辅以手工检索。
  • 纳入调查子宫内膜癌患者接受RALS对比CLS或LT后长期生存结局的文献。
  • 采用固定效应模型或随机效应模型计算合并风险比(HR)和95%置信区间(CI),并评估异质性和发表偏倚。

主要发现

  • RALS与CLS在OS上无差异(HR=0.962,95%CI:0.922-1.004)。
  • RALS与CLS在RFS上无差异(HR=1.096,95%CI:0.947-1.296)。
  • RALS与CLS在DSS上无差异(HR=1.489,95%CI:0.713-3.107)。
  • RALS相比LT与更优的OS显著相关(HR=0.682,95%CI:0.576-0.807)。
  • RALS相比LT与更优的RFS(HR=0.793,95%CI:0.653-0.964)和DSS(HR=0.441,95%CI:0.298-0.652)显著相关。

关键数值与推荐

  • 在效应量测量和随访时间的亚组分析中,RALS的RFS/OS与CLS和LT相比相当或更优。
  • 在早期子宫内膜癌患者中,RALS的OS与CLS相似但RFS更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Robotic-assisted laparoscopy (RALS) has gained widespread acceptance in the field of gynecological oncology. However, whether the prognosis of endometrial cancer after RALS is superior to conventional laparoscopy (CLS) and laparotomy (LT) remains inconclusive. Therefore, the aim of this meta-analysis was to compare the long-term survival outcomes of RALS with CLS and LT for endometrial cancer. METHODS: A systematic literature search was conducted on electronic databases (PubMed, Cochrane, EMBASE and Web of Science) until May 24, 2022, followed by a manual search. Based on inclusion and exclusion criteria, publications investigating long-term survival outcomes after RALS vs CLS or LT in endometrial cancer patients were collected. The primary outcomes included overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS) and disease-free survival (DFS). Fixed effects models or random effects models were employed to calculate the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) as appropriate. Heterogeneity and publication bias were also assessed. RESULTS: RALS and CLS had no difference in OS (HR = 0.962, 95% CI: 0.922-1.004), RFS (HR = 1.096, 95% CI: 0.947-1.296), and DSS (HR = 1.489, 95% CI: 0.713-3.107) for endometrial cancer; however, RALS was significantly associated with favorable OS (HR = 0.682, 95% CI: 0.576-0.807), RFS (HR = 0.793, 95% CI: 0.653-0.964), and DSS (HR = 0.441, 95% CI: 0.298-0.652) when compared with LT. In the subgroup analysis of effect measures and follow-up length, RALS showed comparable or superior RFS/OS to CLS and LT. In early-stage endometrial cancer patients, RALS had similar OS but worse RFS than CLS. CONCLUSIONS: RALS is safe in the management of endometrial cancer, with long-term oncological outcomes equivalent to CLS and superior to LT.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fu H, Zhang J, Zhao S, et al. Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2023. PMID: 37149906. doi:10.1016/j.ygyno.2023.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。